急性淋巴细胞白血病的免疫疗法：从匮乏到富足。
Immunotherapy for acute lymphoblastic leukemia: from famine to feast.
作者信息
Davis Kara L, Mackall Crystal L
机构信息
Department of Pediatrics and.
Department of Medicine, Stanford University, Stanford, CA.
出版信息
Blood Adv. 2016 Dec 27;1(3):265-269. doi: 10.1182/bloodadvances.2016000034.
Abstract
This article has a companion Point by Jabbour and Kantarjian. Join in the discussion of these articles at Community Conversations.
摘要
本文有一篇由贾布尔和坎塔尔吉安撰写的配套观点文章。请在“社区对话”中参与对这些文章的讨论。
相似文献
1
Immunotherapy for acute lymphoblastic leukemia: from famine to feast.急性淋巴细胞白血病的免疫疗法：从匮乏到富足。
Blood Adv. 2016 Dec 27;1(3):265-269. doi: 10.1182/bloodadvances.2016000034.
2
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.成人急性淋巴细胞白血病的免疫疗法：单克隆抗体的作用
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
3
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
4
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
5
Related haploidentical donors are a better choice than matched unrelated donors: Point.相关的单倍体相合供体比匹配的无关供体是更好的选择：观点。
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
6
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
7
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
8
Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.基于血容量的血管性血友病因子用于预防血管性血友病患者产后出血
Blood Adv. 2017 Apr 25;1(11):703-706. doi: 10.1182/bloodadvances.2017005090.
9
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
10
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
引用本文的文献
1
Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD.外周血 MRD 和 18F-FDG PET 在 CAR 复发后的作用：外周血和骨髓 MRD 不一致的病例研究。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-004851.
2
CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.靶向 CD19 的 CD4 CAR-T 细胞在加剧细胞因子释放综合征方面发挥着关键作用，同时保持长期反应。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005878.
3
Development of CAR T Cell Therapy in Children-A Comprehensive Overview.儿童嵌合抗原受体T细胞疗法的发展——全面概述
J Clin Med. 2022 Apr 12;11(8):2158. doi: 10.3390/jcm11082158.
4
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.突触拓扑结构和下调事件决定了抗 CD19 T 细胞重定向策略的功能结果。
Oncoimmunology. 2022 Mar 23;11(1):2054106. doi: 10.1080/2162402X.2022.2054106. eCollection 2022.
5
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.Blinatumomab 无应答和高疾病负担与 CD19-CAR 治疗 B-ALL 后的不良结局相关。
J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12.
6
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.嵌合抗原受体 T 细胞疗法对 CD19 弱表达 B 淋巴细胞白血病有效，但会受到先前blinatumomab 治疗的影响。
Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.
本文引用的文献
1
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.用于B细胞肿瘤的嵌合抗原受体T细胞：为您选择合适的嵌合抗原受体
Curr Hematol Malig Rep. 2016 Oct;11(5):368-84. doi: 10.1007/s11899-016-0336-z.
2
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.CD19 CAR 免疫压力诱导 B 前体细胞急性淋巴细胞白血病谱系转换，揭示内在白血病可塑性。
Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.
3
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
4
Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.博纳吐单抗，一种用于CD-19靶向癌症免疫治疗的双特异性T细胞衔接器（BiTE(®)）：临床药理学及其意义。
Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4.
5
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.博纳吐单抗治疗复发/难治性B前体急性淋巴细胞白血病老年患者：两项2期研究的结果
Cancer. 2016 Jul 15;122(14):2178-85. doi: 10.1002/cncr.30031. Epub 2016 May 3.
6
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.成年B细胞急性淋巴细胞白血病患者中具有特定CD4+:CD8+组成的CD19嵌合抗原受体T细胞。
J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
7
Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.CD19导向治疗后MLL重排婴儿白血病中的谱系转换
Pediatr Blood Cancer. 2016 Jun;63(6):1113-5. doi: 10.1002/pbc.25953. Epub 2016 Feb 23.
8
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.获得性突变与CD19可变剪接的趋同导致对CART-19免疫疗法产生抗性。
Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.
9
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.工程共刺激结构设计决定肿瘤排斥动力学和 CAR T 细胞的持久性。
Cancer Cell. 2015 Oct 12;28(4):415-428. doi: 10.1016/j.ccell.2015.09.004.
10
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.4-1BB共刺激可改善嵌合抗原受体的持续性信号传导所诱导的T细胞耗竭。
Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.
Zotero 插件